Sangamo Therapeutics (SGMOQ) Net Cash Flow Growth (3y) (2013 - 2025)
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.28 Bn | 9.43 Bn | 112.79 Mn | -36.28% |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.76 Bn | 3.46 Bn | 55.72 Mn | 30.02% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -63.92% |
| 5 | uniQure | 3.07 Bn | 3.07 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.34 Bn | 1.54 Bn | 251.87 Mn | 93.57% |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 21.38% |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - | -57.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -57.23% |
| Sep 30, 2025 | 26.18% |
| Jun 30, 2025 | 80.59% |
| Mar 31, 2025 | 32.60% |
| Dec 31, 2024 | 34.66% |
| Sep 30, 2024 | 18.71% |
| Jun 30, 2024 | -37.22% |
| Mar 31, 2024 | 46.72% |
| Dec 31, 2023 | 53.73% |
| Sep 30, 2023 | 63.91% |
| Jun 30, 2023 | -26.63% |
| Mar 31, 2023 | -84.77% |
| Sep 30, 2022 | 3.86% |
| Jun 30, 2022 | -27.96% |
| Mar 31, 2022 | 0.49% |
| Dec 31, 2021 | -56.23% |
| Sep 30, 2021 | -49.98% |
| Jun 30, 2021 | 17.66% |
| Mar 31, 2021 | 25.12% |
| Dec 31, 2020 | -95.36% |